Clarity receives $9.8 million R&D tax incentive refund
Filed with ASX · · 1 page · English
Summary by 6ix AI
This funding will support the development of Clarity's Targeted Copper Theranostic platform aimed at various cancer treatments. The Executive Chairperson, Dr. Alan Taylor, expressed satisfaction with the funding, highlighting its importance for ongoing research and development efforts.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma
- Clarity signs a Commercial Manufacturing Agreement
- Co-PSMA data published in the European Urology journal
- Clarity signs a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics
- Clarity signs a large-scale Manufacturing Supply Agreement
Later from Clarity Pharmaceuticals
- Data on SAR-bisPSMA to be presented at EANM
- Becoming a substantial holder
- Quarterly Activities/Appendix 4C Cash Flow Report
- Ceasing to be a substantial holder
- SECuRE update
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals